Gilead Sciences, Inc. Clinical Trial Services Agreement GILEAD SCIENCES, INC. SMLOUVA O POSKYTOVÁNÍ SLUŽEB KLINICKÉHO HODNOCENÍClinical Trial Services Agreement • January 24th, 2021
Contract Type FiledJanuary 24th, 2021This Clinical Trial Services Agreement (“Agreement”) is made effective as of 29th November, 2016 (“Effective Date”) by and between Gilead Sciences, Inc., a Delaware corporation having a principal place of business at 333 Lakeside Drive, Foster City, California 94404 (together with its affiliates and subsidiaries, “Gilead”) and Revmatologický ústav having an address at Na Slupi 4, 128 50, Praha 2, Czech Republic, company ID number: 00023728, DIČ: CZ00023728, represented by prof. MUDr. Karel Pavelka, DrSc., Director (“Service Provider”). Gilead and Service Provider are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Gilead has contracted with Pharmaceutical Research Associates CZ, s.r.o., located at Jankovcova 1569/2c, Praha 7, 170 00, Czech Republic, company ID number: 27636852, TAX ID number: CZ27636852, the limited liability company duly registered in the Commercial Register of the Czech Republic maintained by the Municipal Court in Prag
Gilead Sciences, Inc. Clinical Trial Services Agreement GILEAD SCIENCES, INC. SMLOUVA O POSKYTOVÁNÍ SLUŽEB KLINICKÉHO HODNOCENÍClinical Trial Services Agreement • November 7th, 2020 • California
Contract Type FiledNovember 7th, 2020 JurisdictionThis Clinical Trial Services Agreement (“Agreement”) is made effective as of 14th October, 2016 (“Effective Date”) by and between Gilead Sciences, Inc., a Delaware corporation having a principal place of business at 333 Lakeside Drive, Foster City, California 94404 (together with its affiliates and subsidiaries, “Gilead”) and Revmatologický ústav having an address at Na Slupi 4, 128 50, Praha 2, Czech Republic, company ID number: 00023728, DIČ: CZ00023728, represented by prof. MUDr. Karel Pavelka, DrSc., Director (“Service Provider”). Gilead and Service Provider are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Gilead has contracted with Quintiles Czech Republic s.r.o., located at Radlická 714/113a, Praha 5, 158 00, Czech Republic (the “CRO”) to serve as Gilead's contract research organization for the Trial. Tato Smlouva o poskytování služeb klinického hodnocení („Smlouva“) je uzavřena k datu účinnosti 14. října, 2016 („Datum účinnosti“),